The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Safety and efficacy of remimazolam in high risk colonoscopy: A randomized trial
Open accessAbstract
BACKGROUND: Procedural sedation of ASA III/IV patients has increased risk. Remimazolam (an ultra-short-acting benzodiazepine) has proven safe and efficient for outpatient colonoscopy sedation. METHODS: A double-blind, randomized, multi-center, parallel group trial was performed, comparing remimazolam to placebo with an additional open-label arm for midazolam in procedural sedation of 79 ASA III/IV patients undergoing colonoscopy. This was the third of 3 Phase III trials for remimazolam in the procedural sedation program. The primary end point was the safety of remimazolam. RESULTS: Of 79 patients randomized at 3 US sites, 77 underwent sedation and colonoscopy (31 received remimazolam, 16 placebo and 30 midazolam). Incidence and frequency of treatment emergent adverse events (TEAEs) were comparable in all three treatment arms, and independent of ASA status. One TEAE leading to discontinuation and one serious TEAE were reported; both in the open label midazolam arm. The efficacy endpoint was achieved for remimazolam, placebo, and midazolam in 87.1%, 0%, and 13.3% of patients (p<0.00001 for remimazolam versus placebo and versus midazolam, respectively). CONCLUSIONS: Remimazolam is safe and efficient in procedural sedation of high risk ASA patients undergoing colonoscopy, showing a safety profile comparable to that in low risk ASA.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Guidelines for sedation and anesthesia in GI endoscopy
Early, D. S., Lightdale, J. R., Vargo, J. J., Acosta, R. D., Chandrasekhara, V., Chathadi, K. V., Evans, J. A., Fisher, D. A., Fonkalsrud, L., Hwang, J. H., et al. (2018) · Gastrointestinal Endoscopy · doi:10.1016/j.gie.2017.07.018 · Cited by 679
Wiltshire, H. R., Kilpatrick, G. J., Tilbrook, G. S., & Borkett, K. M. (2012) · Anesthesia & Analgesia · doi:10.1213/ane.0b013e318241f68a · Cited by 215
Cited by
Remimazolam: non-clinical and clinical profile of a new sedative/anesthetic agent
Kilpatrick, G. J. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.690875 · Cited by 262
Remimazolam: pharmacological characteristics and clinical applications in anesthesiology
Kim, K. M. (2022) · Anesthesia and Pain Medicine · doi:10.17085/apm.21115 · Cited by 257
Remimazolam: a review in procedural sedation
Lee, A., & Shirley, M. (2021) · Drugs · doi:10.1007/s40265-021-01544-8 · Cited by 194
Guo, J., Qian, Y., Zhang, X., Han, S., Shi, Q., & Xu, J. (2022) · BMC Anesthesiology · doi:10.1186/s12871-022-01713-6 · Cited by 153
Efficacy and safety of remimazolam in endoscopic sedation-A systematic review and meta-analysis
Zhu, X., Wang, H., Yuan, S., Li, Y., Jia, Y., Zhang, Z., Yan, F., & Wang, Z. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.655042 · Cited by 75
Metadata
- Authors
- Rex, D. K., Bhandari, R., Lorch, D. G., Meyers, M., Schippers, F., & Bernstein, D.
- Venue
- Digestive and Liver Disease
- Publisher
- Elsevier BV
- Published
- 2021-01
- Volume
- 53
- Issue
- 1
- Pages
- 94-101
- ISSN
- 1590-8658 (ISSN-L)
- OpenAlex
- W3108671470
- Cited by
- 164
- References
- 2
- FWCI
- 16.10
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.